Hans-Christoph Diener

Hans-Christoph Diener

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Hans-Christoph Diener

Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Faculty of Medicine, University Duisburg-Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in The Lancet
Verified
Journal Article
Closed access
HDHans-Christoph Diener
Hans-Christoph Diener
JBJulien Bogousslavsky
Julien Bogousslavsky
LBLawrence M Brass
Lawrence M Brass
CCClaudio Cimminiello
Claudio Cimminiello
LCLaszlo Csiba
Laszlo Csiba
HRHans-Jürgen Rupprecht
Hans-Jürgen Rupprecht

16 May 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
HDHans-Christoph Diener
Hans-Christoph Diener
RSRalph L. Sacco
Ralph L. Sacco
JEJ. Donald Easton
J. Donald Easton
CGChristopher B. Granger
Christopher B. Granger
RBRichard A. Bernstein
Richard A. Bernstein
KTKazunori Toyoda
Kazunori Toyoda
Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran would be effective in preventing recurrent strokes after this type of stroke was unclear.

18 June 2021 in Nature Reviews Neurology
Verified
Journal Article
Open access
PDF file
AEAnna K. Eigenbrodt
Anna K. Eigenbrodt
HAHåkan Ashina
Håkan Ashina
SKSabrina Khan
Sabrina Khan
HDHans-Christoph Diener
Hans-Christoph Diener
DMDimos D. Mitsikostas
Dimos D. Mitsikostas
MAMessoud Ashina
Messoud Ashina
Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up.

9 November 2021 in Circulation
Verified
Journal Article
Open access
PDF file
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy
DTDavid Thaler
David Thaler
CEChristopher R. Ellis
Christopher R. Ellis
VSVijendra Swarup
Vijendra Swarup
LSLars Sondergaard
Lars Sondergaard
SWStephan Windecker
Stephan Windecker
Background: Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with nonvalvular atrial fibrillation. The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed to evaluate the safety and effectiveness of the dual-seal mechanism of the Amulet LAA occluder compared with the Watchman device. Methods: Patients with nonvalvular atrial fibrillation at increased risk of stroke were randomly assigned (1:1) to undergo percutaneous implantation of a LAA occluder with the Amulet occluder or Watchman device. The primary end points included safety (composite of procedure-related complications, all-cause death, or major bleeding at 12 months), effectiveness (composite of ischemic stroke or systemic embolism at 18 months), and the rate of LAA occlusion at 45 days. Prespecified secondary end points included a composite of all stroke, systemic embolism, or cardiovascular/unexplained death at 18 months, major bleeding at 18 months, and superiority test of the 3 primary end points. Results: A total of 1878 patients were enrolled. The Amulet occluder was noninferior to the Watchman device for the primary safety end point (14.5% versus 14.7%; difference=–0.14 [95% CI, –3.42 to 3.13]; P <0.001 for noninferiority). Major bleeding and all-cause death were similar between groups (10.6% versus 10.0% and 3.9% versus 5.1%, respectively). Procedure-related complications were higher for the Amulet occluder (4.5% versus 2.5%), largely related to more frequent pericardial effusion and device embolization. The Amulet occluder was noninferior to the Watchman device for the primary effectiveness end point (2.8% versus 2.8%; difference=0.00 [95% CI, –1.55 to 1.55]; P <0.001 for noninferiority), and the composite of stroke, systemic embolism, or cardiovascular/unexplained death (5.6% versus 7.7%, difference=–2.12 [95% CI, –4.45 to 0.21]; P <0.001 for noninferiority). The rate of major bleeding was similar between groups (11.6% versus 12.3%; difference=–0.71 [95% CI, –3.72 to 2.31]; P =0.32 for superiority). LAA occlusion was higher for the Amulet occluder than for the Watchman device (98.9% versus 96.8%; difference=2.03 [95% CI, 0.41–3.66]; P <0.001 for noninferiority; P =0.003 for superiority). Conclusions: The Amulet occluder was noninferior for safety and effectiveness of stroke prevention for nonvalvular atrial fibrillation compared with the Watchman device and superior for LAA occlusion. Procedure-related complications were higher with the Amulet occluder and decreased with operator experience. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02879448.

1 December 2010 in The Lancet Neurology
Verified
Journal Article
Closed access
HDHans-Christoph Diener
Hans-Christoph Diener
SCStuart J Connolly
Stuart J Connolly
MEMichael D Ezekowitz
Michael D Ezekowitz
LWLars Wallentin
Lars Wallentin
PRPaul A Reilly
Paul A Reilly
RGRE-LY study group
RE-LY study group

1 August 2004 in The Lancet Neurology
Verified
Journal Article
Closed access
HDHans-Christoph Diener
Hans-Christoph Diener
VLVolker Limmroth
Volker Limmroth